Pharma R&D Efficiency: Mid-Sized Companies Excel
Datamonitor Healthcare's recent review of R&D efficiency using new product launch success rates as a proxy shows that Mid Pharma companies outperform Big Pharma and Japan Pharma firms, thanks to multiple blockbuster drugs. The first in a two-part series evaluating R&D productivity.
You may also be interested in...
Datamonitor Healthcare's mid pharma peer set, a group that boasts efficiency in R&D but still relies on business development for growth, has signed a significant number of alliances over the past six years to build out the pipeline in innovative areas.
Datamonitor Healthcare's measurement of pharma R&D return on investment finds that Mid Pharma companies outperform on an ROI index. The second in a two-part series evaluating R&D productivity.
The high risk-high reward nature of drug development is a constant challenge to pharma. Informa's Pharma Intelligence teamed up with BIO and Amplion to provide an update on clinical development success rates from 2006 to 2015, including a new analysis on trials incorporating patient selection biomarkers.